We recently purchased one of these machines and are currently enrolled in an FDA study on pain. While researching the treatment in detail I found a number of studies on its use in lymphoma.
Extracorporeal photopheresis (ECP) (also known as Ultraviolet Blood Irradiation or UVBI) has been used for the treatment of advanced stage or treatment refractory cutaneous T-cell lymphoma (CTCL) since 1987, and more recently has also been shown to be of benefit for earlier stage resistant CTCL.This recent study (reference below) showed that the twelve-month response to ECP was 90%: 15 patients (75%) had complete responses, 3 (15%) had partial responses, 1 had stable disease, and 1 progressed.
J Drugs Dermatol. 2016 Oct 1;15(10):1212-1216. 75% Complete Response and 15% Partial Response to Extracorporeal Photopheresis Combined With Other Therapies in Resistant Early Stage Cutaneous T-Cell Lymphoma.